Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTC21C plus VCd vs VCd in newly diagnosed systemic light chain amyloidosis
CTR20254956Phase 3Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SCTC21C in light-chain amyloidosis, sponsored by Sinocelltech Group Limited. Started Dec 2025; status: active.
02
Drugs
SCTC21C
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on CTR20254956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254956.